厚无生物医药

Houwu Biomedical is a Shanghai-based biotechnology company specializing in the development of next-generation targeted protein degradation (TPD) therapies. The company leverages its proprietary platform to design and optimize Proteolysis Targeting Chimeras (PROTACs) and molecular glues aimed at previously undruggable targets. Their primary focus is on addressing unmet medical needs in oncology and autoimmune diseases. Houwu is positioned within the vibrant Zhangjiang Hi-Tech Park ecosystem, benefiting from advanced R&D infrastructure and local talent. The company's pipeline is currently in the pre-clinical stage, focusing on high-value targets with the potential for superior efficacy and safety profiles.